why choose us

First received: September 23, 2022

Clinical Trial: 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors

Study Status: Completed

Recruit Status: RECRUITING

Condition: Cervical Cancer

Study Type: INTERVENTIONAL


Official Title: Study of 89Zr-girentuximab for PET Imaging of Solid Tumors Likely to Express High Levels of CAIX

Brief Summary: A prospective, open-label, phase 2 study to explore CAIX expression through 89Zirconium-labelled girentuximab deferoxamine (89Zr-girentuximab) PET/CT imaging in patients with solid tumors.

Read more